✦ LIBER ✦

PCN99 Cost-Effectiveness of Dasatinib versus High-Dose Imatinib and Nilotinib in Patients with Chronic Myeloid Leukaemia Resistant to Standard-Dose Imatinib in Portugal

✍ Scribed by Darba, J.; Kaskens, L.; Abecasis, M.; Vitorino, R.; Carrasco, J.

Book ID: 122112369
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 58 KB
Volume: 14
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2011.08.1200

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN13 Cost-Effectiveness Analysis of Nil

PCN13 Cost-Effectiveness Analysis of Nilotinib Versus Dasatinib in Patients With Imatinib-Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia (CML)

✍ Niu, X.; Hay, J. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PCN75 ECONOMIC EVALUATION OF DASATINIB I

PCN75 ECONOMIC EVALUATION OF DASATINIB IN CHRONIC MYELOGENOUS LEUKAEMIA PATIENTS RESISTANT TO IMATINIB IN PERU, COMPARED TO NILOTINIB AND HIGH DOSES OF IMATINIB

✍ J.J. Orozco Giraldo; J.E. Valencia; S. Garrido Lecca; E.C. Aiello 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PCN69 COST-EFFECTIVENESS ANALYSIS OF DAS

PCN69 COST-EFFECTIVENESS ANALYSIS OF DASATINIB 100 MG VS. IMATINIB 800 MG IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA IN SPAIN

✍ de Ramirez; A Arellano; U Sbarigia; MJ Taylor; P Martin; G Restovic 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

Cytogenetic and molecular responses in c

Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose

✍ Massimo Breccia; Laura Cannella; Caterina Stefanizzi; Roberto Latagliata; Mauro 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

## Abstract Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and 400 mg/day is considered the standard dose. Although it is generally well tolerated, some patients require temporary drug discontinuation and permanent dose reduction because of haematological or non

Cost-Utility Analysis of Dasatinib and N

Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in Thailand

✍ Kulpeng, Wantanee; Sompitak, Sumalai; Jootar, Saengsuree; Chansung, Kanchana; Te 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 433 KB

PCN14 THE COST AND COST EFFECTIVENESS OF

PCN14 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) 100 MG THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS IN CHRONIC PHASE WITH CHRONIC MYELOID LEUKEMIA (CML) IN MÉXICO

✍ Juarez-Garcia, A; Uc-Coyoc, R; Hernandez-Rivera, G; Rangel, S; Taylor, MJ; Lital 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB